ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Allogeneic BAFF-L-expressing CAR T Cells LMY-922

Its studies are mostly in Arthritis, Rheumatoid · Lymphoma, Non-Hodgkin, led by Luminary Therapeutics.

Furthest: phase 1, since Jun 22, 20262 company-led studies, 2 open or runningNext primary completion: Apr 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Luminary Therapeutics22 open or runningphase 1since Jun 22, 2026Jun 22, 2026Apr 2029phase 1 · NCT07679919

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 22, 2026First study: phase 1 study in Lymphoma, Non-HodgkinFirst studyNCT07679919 · 27 planned · United States
  2. Jul 15, 2026Phase 1 study in Arthritis, RheumatoidNCT07729995 · 94 planned · United States

Ahead

  1. Apr 2029Primary completion: phase 1 study in Lymphoma, Non-HodgkinNCT07679919
  2. Mar 2030Primary completion: phase 1 study in Arthritis, RheumatoidNCT07729995

TargetBeta

CD4 →read by rule
“A preparation of allogeneic cluster of differentiation 4 (CD4)-positive and CD8-positive, gamma/delta-specific, T-lymphocytes that are genetically engineered, using the non-viral transposon system, to express a chimeric antigen receptor (CAR) expressing the B-cell activation factor ligand (BAFF-L) a”NCIt, by rule

Other programs on CD4

ProgramCompanyFurthest phaseStudies
zamtocabtagene autoleucelrulemiltenyi-biomedicine-gmbhphase 28
VRC07-523LSruletaimed-biologics-incphase 23
TMB-365ruletaimed-biologics-incphase 23

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07729995Arthritis, Rheumatoid · United States1Not yet recruitingMar 203094
NCT07679919Lymphoma, Non-Hodgkin · United States1Not yet recruitingApr 202927

How it is read

Names in the registry

  • “LMY-922”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.